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RESPIRATORY DISTRESS IN PATIENTS OF GUILLAIN-BARRE 
SYNDROME WITH SENSORY MANIFESTATIONS
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Dr Maher Bano Malik ,  Dr Haris Majid Rajput , Dr Jahangir Shoro , 
ABSTRACT:
INTRODUCTION: Guillain-Barré syndrome (GBS) is one of the most frequent disorder of peripheral nervous 
system associated with respiratory distress. One clinical parameter that was found signiﬁcant in heralding the 
onset of respiratory failure in GBS weresensory manifestations. The aim of the study was to determine the 
frequency of respiratory distress in patients of GuillainBarresyndrome with or without sensory manifestations in the 
disease. MATERIALS AND METHODS: This was a descriptive case seriesthat was conducted from January 19, 
2013 to July 18, 2013 in Department of Neurology, Pakistan Institute of Medical Sciences, Islamabad. All patients 
who met the inclusion criteria were selected for the study. Sensory manifestations of GBS were determined 
clinically, and patients were divided into two groupsi.e patients with sensory manifestations and without sensory 
manifestations. These two groups were followed for a period of 10 days and monitored for the presence of 
respiratory distress. RESULTS: A total of 110 patients were included. The mean age of patients was 34.41 years 
with standard deviation of 17.12 years. 76 (69.09%) patients were male and 34 (30.91%) patients were female. 85 
patients had sensory manifestations while 25 patients had no sensory manifestations. 33 patients of GBS with 
sensory manifestation had respiratory distress while 52 patients had no respiratory distress.CONCLUSION: In our 
study moderate to severe pain is a common and early symptom of Guillain-Barre Syndrome. Respiratory 
involvement is more common in patients with sensory manifestation. Early detection and aggressive treatment of 
sensory manifestations of GuillainBarresyndrome should be a part of initial management so as to minimize the risk 
of respiratory failure.
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INTRODUCTION:
Guillain-Barre syndrome is an acute, post-infectious, 
autoimmune disease involving the demyelination of 
peripheral nerves leading to loss of nerve signaling 
and symmetrical ascending paralysis. Symptoms of a 
preceding upper respiratory or gastrointestinal tract 
infection are present. Campylobacter jejuni, 
Cy tomega lov i rus ,  Eps te in  bar r  v i rus  and 
mycoplasma pneumonia are the predominant 
causes.1-3These infectious agents may induce 
antibody production against gangliosides and 
glycolipids of myelin in the peripheral nerves. The 
annual incidence varies from 0.4 to 4.0 cases per 
100,000 persons with a median incidence of 2 cases 
4,5
per 100,000 population.
Guillain Barré syndrome (GBS) is one of the most 
frequent disorder of peripheral  nervous system 
assoc ia ted  w i th  resp i ra to ry  d is t ress .1  A t 
presentation, about 40% patients have respiratory  
weakness and respiratory failure requiringventilatory 
support occurs in up to one third of patients at some 
6 
time during the course of their disease.  Sensory 
symptoms are paresthesias and numbness in toes 
and ﬁngers, more than half of patients complain of 
aches and pains in muscles, few patients have 
burning sensations in ﬁngers and toes, by the end of 
ﬁrst week of onset, vibration and joint position sense 
in ﬁngers and toes are reduced, deep sensibility 
(touch, pressure, vibration) are more affected than 
7,8.
superﬁcial sensations (pain, temperature) .Few 
studies have demonstrated the association of 
sensory manifestations of GuillainBarresyndrome 
9
with respiratory distress  but so far to our knowledge 
this topic is not studied locally in our setup. The aim of 
the study was to determine and compare the 
frequency of respiratory distress in patients of 
GuillainBarre Syndrome who present with and 
without sensory manifestations in our population so 
as to aid in early detection of onset of respiratory 
failure in the affected individuals.
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MATERIALS AND METHODS:
This was a descriptive case study conducted in the 
Department of Neurology, Pakistan Institute of 
Medical Sciences,Islamabad for six months 
fromJanuary 19, 2013 to July 18, 2013 after taking 
permission from ethical committee of hospital.A total 
of 110 patients of GuillainBarresyndrome were 
enrolled using non probability consecutive sampling. 
Sample size was calculated using WHO sample size 
calculator. An informed written consent was taken 
from all the patients. All patients of both genders 
above 13 years of age,with GuillainBarre Syndrome 
( d i a g n o s e d  o n  b a s i s  o f  c l i n i c a l  a n d 
electrophysiological criteria) were enrolled in this 
study.Diagnostic criteria for GBS was deﬁned from 
the NationalInstitute of Neurological Disorders and 
St roke (NINDS).  Accord ing to  which the 
9
requiredfeatures for the diagnosis of GBS are: 
Progressive weakness of more than one limb 
andareﬂexia. While Supportive features (If any two of 
the following are present) are:Progression of 
symptoms over days to four weeks, Relative 
symmetry, sensory signs/symptoms, Cranial nerve 
involvement, Autonomic dysfunction, CSF protein 
>45 mg/dl, cell count <10 mm3.Electrodiagnostic 
abnormalities for diagnosis of demyelinating variant 
of GBS (If any two of the following four are present): 
are, Prolonged distal latencies in two or more nerves, 
Slowing of Conduction Velocity in two or more 
nerve,Prolonged F response in one or more nerves, 
Conduction block in one or more nerves.  While for 
10 
the axonal variants of Guillainbarre syndrome criteria 
was set as no evidence of demyelination, but reduced 
amplitudes of compound muscle action potentials ( 
CMAP) in two or more motor nerves in AMAN while for 
AMSAN, in addition to the criteria set for AMAN(i.e no 
evidence of demyelination and reduced amplitudes of  
motor CMAPs), reduction of sensory nerve action 
potentials (SNAPs) in two or more nerves. For Miller 
ﬁsher variant reduced or absent SNAPs without 
involvement of motor nerves and no evidence of 
demylination.11Sensory manifestations were 
determined clinically if patients complained of muscle 
pains and aches,paresthesias (burning, tingling, pins 
and needles sensations), numbness in ﬁngers and 
toes, impaired pinprick , joint position and vibration 
sensations. Respiratory distress was deﬁned as if 
single breath count is less than 20.
7
Those patients who had a sensory level, having 
systemic illness other than Guillain-Barre Syndrome 
associated with neuropathy that could lead to chronic 
sensory symptoms on historical inquiry e.g. Diabetes 
mel l i tus,  chronic  renal  fa i lure,  heredi tary 
neuropathies and toxin exposure,use of drugs 
causing peripheral neuropathy e.gAntituberculous 
drugs, Metronidazole, Amiodarone, Phenytoin, 
Lithium and Hypokalemic paralysis (serum  < 3.0 
mmol/lit) were excluded. Patients who fulﬁlled the 
criteria underwent detailed history and neurological 
examination. Patients were divided into two groups 
i.e. patients with sensory manifestations and without 
sensory manifestations, these two groups was 
followed for a period of 10 days and monitored for the 
presence of respiratory distress. The data was 
entered on a standardized Performa. Data was 
entered and analyzed using SPSS version 17. Mean 
and standard deviation was calculated for numerical 
variables (age). Frequencies and percentages were 
calculated for categorical variables (gender, sensory 
signs and symptoms and respiratory distress). 
Chi square test was used to compare the presence of 
respiratory distress between the two groups. P value 
< 0.05 was considered signiﬁcant for all the results.
RESULTS:
A total of 110 patients were included in this study. The 
mean age of patients was 34.41±17.12.Out of 110 
patients, 76 (69.09%) patients were male and 34 
(30.91%) patients were females. 
85 patients had sensory manifestations while 25 
patients had no sensory manifestations as shown in 
ﬁgure no: 1
55 male patients had sensory manifestation while 21 
patients had no sensory manifestations and 30 
female patients had sensory manifestations while 4 
patients had no sensory manifestations with 
insigniﬁcant p value of 0.066 as shown in table no: 1.
There was no signiﬁcant age predi lect ion
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Figure no: 1
Sensory manifestations in different patients
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Table no: 1
Sensory manifestations in different gender of patients
Out of 110 patients, 33 patients had respiratory distress 
while 77 patients had no
respiratory distress as shown in ﬁgure no: 2
Figure no:2
Frequency of respiratory distress in different patients
24 male patients had respiratory distress while 52 
patients had no respiratory distress
and 9 female patients had respiratory distress while 
25 patients had no respiratory 
distress with insigniﬁcant p value of 0.589 as shown in 
table no: 2 while there was no signiﬁcant age 
predilection.
Table no: 2
Respiratory distress in different gender of patients
33 patients of GBS with sensory manifestation had 
respiratory distress while 52 patients had no 
respiratory distress and 25 patients of GBS without 
sensory manifestation had no respiratory distress with 
signiﬁcant p value of 0.001 as shown in table no: 3
Table no: 3
Respiratory distress in patients with and without sensory 
manifestations
DISCUSSION:
GB syndrome is one of the severe forms of 
polyneuropathies with variable sensory symptoms, 
motor disability, need for hospitalization and 
uncertainty of the course of the disease. Sensory 
disturbances, especially pain, are common in GBS.  
12 
The major reason for mechanical ventilation is 
respiratory muscle weakness and inability to clear 
secretions.These symptoms often follow ascending 
extremity weakness but can appear with minimal limb 
involvement or uncommonly as the sole presenting 
feature of illness. The pace of progression of 
respiratory failure from onset can be dramatic, 
necessitating the need for ventilator support over 24 
to 48 hours. Alternatively the progression can be sub-
acute, or progressing gradually over 3 to 4 weeks. A 
13 
careful examination including single breath count, 
along with arterial blood gases and bed side 
pu lmonary  func t ion  tes ts  a re  o f  ex t reme 
importance.14The general recommendation is to 
intubate these patients when the vital capacity falls to 
approximately 15  mL/kg. Early predictors of need 
15 
for mechanical ventilation includedifﬁculty in clearing 
secretions because of inability to cough, inability to lift 
elbows and headand bulbar weakness because of 
resultant lack of oropharyngeal protect ive 
mechanisms.  Literature has many studies 
15,16
showing the prevalence of sensory symptoms 
predominately pain in patients with GuillainBarre 
syndrome in the acute phase of illness and its impact 
on long term outcome in these patients , However, 
17,18
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there are only few focused studies in the literature 
abou t  t he  assoc i a t i on  o f  t hese  senso ry 
manifestations with respiratory distress in patients of 
GuilainBarre syndrome. So more focus is required to 
detect the sensory symptoms for early prediction of 
the heralding respiratory failure in these patients.In 
our study, out of 110 patients the frequency of sensory 
manifestation was 77.27% and these manifestations 
were absent in 22.73% patients.33 patients (30.0%) 
had respiratory distress. 76 (69.09%) patients were 
male and 34 (30.91%) were female. The mean age 
was 34.41±17.12. On comparing various parameters 
among patients with GBS with and without sensory 
manifestations, the only statistically signiﬁcant 
difference was the presence of respiratory 
involvement in those with sensory manifestations. 
None of the other factors or predilection of these 
sensory symptoms and respiratory distress for age or 
gender were signiﬁcant.These results were 
comparable to the results of other international 
studies. Karkare et al studied a cohort of 60 patients 
of GuillainBarre syndrome and found sensory 
dysfunction in 48 (80%) patients,  pain in 30 ( 50%), 
paresthesias in 45 (75%), sensation of pain and temp, 
joint position and vibration were impaired in 8 
(13.3%), 14 (23.3%) and 11 (18.3%) patients 
respectively. Pain assessment using VAPAR(visual 
analogue for paresthesias), VAP (visual analogue for 
pain) and VERP (verbal rating scale for pain) from 
Day 1 to Day 10 of hospitalization was done. On 
comparing various parameters among patients of 
GuillainBarre syndrome with (39 patients) and 
without pain and paresthesias(21patients), 
statistically signiﬁcant difference was presence of 
respiratory involvement in 8 patients (20.5 % and p 
value = 0.02) with pain and paresthesias and in none 
of the patients with out sensory menifestations. A 
9 
study conducted by Taly AB et al  showed that 
19
sensory symptoms or signs were present in 45% and 
59% of patients of GBS in upper and lower limbs 
respectively and were distal and symmetrical. 
Impairment of joint position and vibration sense was 
the commonest ﬁnding and was associated with a 
greater need for ventilatory support and autonomic 
disturbances.Ruts et al  recently described 156 
20
patients with GB syndrome and pain was reported 2 
weeks preceding weakness in 36% of patients, 66% 
reported pain in the acute phase (ﬁrst 3 weeks after 
inclusion), and 38% reported pain after 1 year. In the 
majority of patients, the intensity of pain was 
moderate to severe. Longitudinal analysis showed 
high mean pain intensity scores during the entire 
follow-up. Pain occurred in the whole spectrum of 
GBS. The mean pain intensity was predominantly 
high in patients with GBS, patients with sensory 
disturbances, and severely affected patients. Only 
during later stages of disease, severity of weakness 
and disability were signiﬁcantly correlated with 
intensity of pain.Walling AD et  showed that the 
21
al
most  common form of  the disease,  acute 
inﬂammatory demyelinating polyradiculoneuropathy, 
presents as progressive motor weakness, usually 
beginning in the legs and advancing proximally. 
Symptoms typically peak within four weeks, then 
plateau before resolving. More than one-half of 
patients experience severe pain, and about two-thirds 
have autonomic symptoms, such as cardiac 
arrhythmias, blood pressure instability, or urinary 
retention. Advancing symptoms may compromise 
respiration and vital functions.In the current study, 
several limitations need to be recognized. The 
patients recruited were not critically ill as this might 
have hampered their participation in a questionnaire-
based enquiry. Another l imitation was non-
consecutive selection of subjects depending on the 
feasibility of evaluation by the investigator. Further, 
patients were admitted on different days of their illness 
as is observed in the majority of the studies involving 
GBS. The electrophysiological studies were carried 
out early and on variable days of hospitalization.
CONCLUSION:
Sensory manifestations in Guillain-Barre Syndrome 
are often under-recognized and under-emphasized. 
Respiratory involvement is more common in patients 
with sensory manifestation than in those without 
sensory manifestations.These symptoms require 
early detection to categorize the patients who are at 
risk of respiratory failure and hence aggressively 
managed so as to improve symptomatic proﬁle and 
quality of life.  
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